Media headlines about NeuroDerm (NASDAQ:NDRM) have been trending somewhat positive on Tuesday, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NeuroDerm earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.5995993823955 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Neuroderm Ltd (NDRM) MFI Reading Under the Microscope - Evergreen Caller (evergreencaller.com)
- Weekly Performance of Healthcare stock: NeuroDerm Ltd. (NDRM) stock fluctuated 17.02% higher - Street Observer (press release) (streetobserver.com)
- Neuroderm Ltd (NDRM) Triple EMA Picking up Steam - Evergreen Caller (evergreencaller.com)
- Neuroderm Ltd (NDRM): Ichimoku Levels in Focus - Evergreen Caller (evergreencaller.com)
- NeuroDerm Ltd. (NDRM) and Synthesis Energy Systems, Inc. (SYMX) in Intentions Seekers - Investing News Update (investingbizz.com)
Shares of NeuroDerm (NASDAQ:NDRM) traded down 0.13% during trading on Tuesday, hitting $38.65. The stock had a trading volume of 393,674 shares. NeuroDerm has a 52 week low of $15.20 and a 52 week high of $38.85. The company’s market capitalization is $1.02 billion. The firm has a 50-day moving average price of $30.96 and a 200 day moving average price of $26.58.
NeuroDerm (NASDAQ:NDRM) last issued its earnings results on Thursday, May 11th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.13. Equities analysts anticipate that NeuroDerm will post ($2.00) earnings per share for the current year.
Several analysts recently weighed in on the company. CIBC raised NeuroDerm from a “market perform” rating to an “outperform” rating and set a $42.00 price objective on the stock in a research note on Wednesday, June 14th. Deutsche Bank AG assumed coverage on NeuroDerm in a research note on Friday, July 21st. They issued a “buy” rating and a $47.00 price objective on the stock. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of NeuroDerm in a research note on Sunday, April 23rd. Zacks Investment Research lowered NeuroDerm from a “buy” rating to a “hold” rating in a research note on Wednesday, April 5th. Finally, Roth Capital set a $33.00 price objective on NeuroDerm and gave the company a “buy” rating in a research note on Wednesday, June 14th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $43.38.
NeuroDerm Company Profile
NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.
Receive News & Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
